3-((4-(4-amino-6-((3-chlorophenyl)amino)-1,3,5-triazin-2-yl)-2-pyridinyl)amino)-1-propanol | 652153-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 3-((4-(4-amino-6-((3-chlorophenyl)amino)-1,3,5-triazin-2-yl)-2-pyridinyl)amino)-1-propanol
• 英文别名: 3-{4-[4-Amino-6-(3-chloro-phenylamino)-[1,3,5]triazin-2-yl]-pyridin-2-ylamino}-propan-1-ol；3-[[4-[4-amino-6-(3-chloroanilino)-1,3,5-triazin-2-yl]pyridin-2-yl]amino]propan-1-ol
• CAS: 652153-55-4
• 化学式: C₁₇H₁₈ClN₇O
• 分子量: 371.829
• InChiKey: GASCNUBLHQPAMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  122
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-氯吡啶-4-甲酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 114.0h， 生成 3-((4-(4-amino-6-((3-chlorophenyl)amino)-1,3,5-triazin-2-yl)-2-pyridinyl)amino)-1-propanol
  参考文献：
  名称：

  Synthesis and Identification of [1,3,5]Triazine-pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors

  摘要：

  On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474 and compound B led to the discovery of [1,3,5]triazine-pyridine as a new series of potent CDK inhibitors. Palladium-catalyzed C-C bond formation reactions, particularly the Negishi coupling reaction, were used to assemble various triazine-heteroaryl analogues effectively. Among them, compound 20 displayed high inhibitory potency at CDK1 IC50 = 0.021 mu M), CDK2, and CDK5 and submicromolar potency at CDK4, CDK6, and CDK7. Compound 20 also displayed high potency at GSK-3 beta. It demonstrated potent antiproliferative activity on various tumor cell lines, including HeLa, HCT-116, U937, and A375. When 20 was administered intraperitoneally at 150 and 125 mg/kg to nude mice bearing human A375 xenografts, the compound produced a significant survival increase. Molecular docking studies were conducted in an attempt to enhance the understanding of the observed structure-activity relationship.

  DOI：

  10.1021/jm040214h

文献信息

• [EN] SUBSTITUTED TRIAZINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DES KINASES A BASE DE TRIAZINE SUBSTITUEE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004009562A1

  公开（公告）日：2004-01-29

  The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.

  本发明提供了替代的1,3,5-三嗪化合物作为激酶抑制剂，并提供了一种治疗或改善激酶介导的疾病的方法。
• [EN] N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS DE N,6-BIS(ARYL- OU HÉTÉROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE À TITRE D'INHIBITEURS DES MUTANTS IDH2 POUR LE TRAITEMENT DU CANCER
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2015006592A1

  公开（公告）日：2015-01-15

  Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.

  提供的是化合物的结构式（I），其中：环A和环B分别是可选择地取代的5-6成员单环芳基或杂环芳基。这些化合物是异柠檬酸脱氢酶2（IDH2）突变体的抑制剂，可用于治疗癌症。
• N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：AGIOS PHARMACEUTICALS, INC.

  公开号：US20160158241A1

  公开（公告）日：2016-06-09

  Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.

  提供的化合物的化学式为（I），其中：环A和环B各自独立地是可选取代的5-6成员单环芳基或杂芳基。这些化合物是异柠檬酸脱氢酶2（IDH2）突变体的抑制剂，可用于治疗癌症。
• Substituted triazine kinase inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：EP2256108A1

  公开（公告）日：2010-12-01

  The present invention provides substituted 1,3,5-triazine compounds of Formula (I): wherein X, Y and Z are independently selected from the group consisting of CH and N; wherein m is an integer from 2 to 5; wherein X, Y and Z include at least one CH atom and at least one N atom; and, wherein a N atom may simultaneously occupy only the X and Z positions; R1 is selected from the group consisting of hydrogen and NH2; and, R2 is selected from the group consisting of phenyl (wherein phenyl is substituted with one substituent selected from the group consisting of halogen and heterocyclyl) and 1,4-benzodioxinyl; and pharmaceutically acceptable salts thereof as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.

  本发明提供了式 (I) 的取代 1,3,5 三嗪化合物： 其中 X、Y 和 Z 独立地选自由 CH 和 N 组成的组；其中 m 是 2 至 5 的整数；其中 X、Y 和 Z 包括至少一个 CH 原子和至少一个 N 原子；其中一个 N 原子可以同时只占据 X 和 Z 的位置； R1 选自由氢和 NH2 组成的组；以及 R2 选自苯基（其中苯基被一个选自卤素和杂环基的取代基取代）和 1,4-苯并二噁烷基； 及其药学上可接受的盐，作为激酶抑制剂和一种治疗或改善激酶介导的疾病的方法。
• N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US10111878B2

  公开（公告）日：2018-10-30

  Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.

  提供了式(I)化合物 其中：环 A 和环 B 各自独立地为任选取代的 5-6 位单环芳基或杂芳基。这些化合物是异柠檬酸脱氢酶 2（IDH2）突变体的抑制剂，可用于治疗癌症。